brofaromine
Sign in to saveAlso known as Consonar
Brofaromine (proposed brand name Consonar) is a reversible inhibitor of monoamine oxidase A (RIMA) discovered by Ciba-Geigy. The compound was primarily researched in the treatment of depression and anxiety but its development was dropped before it was brought to market.
Research
166 papers- Brofaromine in endogenous depression.Progress in neuro-psychopharmacology & biological psychiatry · 1994
- Pharmacological treatments in panic disorder in adults: a network meta-analysis.The Cochrane database of systematic reviews · 2023
- Newer aspects of the reversible inhibitor of MAO-A and serotonin reuptake, brofaromine.Progress in neuro-psychopharmacology & biological psychiatry · 1993
- Efficacy of pharmacotherapies for bulimia nervosa: a systematic review and meta-analysis.BMC pharmacology & toxicology · 2023
- Brofaromine: a monoamine oxidase-A and serotonin uptake inhibitor.Clinical neuropharmacology · 1993
via PubMed
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 309.036
Show 4 more facts
- canonical SMILES
- COC1=CC(=C2C(=C1)C=C(O2)C3CCNCC3)Br
- chemical formula
- C₁₄H₁₆BrNO₂
- subject has role
- monoamine oxidase inhibitor
- Commons category
- Brofaromine
Sources (2)
via Wikidata · CC0
~1 min read
Encyclopedic overview
3 sectionsContents
- Pharmacology
- See also
- References
Brofaromine (proposed brand name Consonar) is a reversible inhibitor of monoamine oxidase A (RIMA) discovered by Ciba-Geigy. The compound was primarily researched in the treatment of depression and anxiety but its development was dropped before it was brought to market.
Brofaromine also acts as a serotonin reuptake inhibitor, and its dual pharmacologic effects offered promise in the treatment of a wide spectrum of depressed patients while producing less severe anticholinergic side effects in comparison with older standard drugs like certain of the tricyclic antidepressants.
Excerpted from Wikipedia’s “brofaromine” article, available under the CC BY-SA 4.0 licence.